Literature DB >> 26047596

Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function.

Cuma Bulent Gul1, Abdulmecit Yildiz, Alparslan Ersoy, Serdar Kahvecioglu, Burak Asiltas, Fatih Yildirim, Selime Ermurat, Saim Sag, Aysegul Oruc, Sumeyye Gullulu, Mustafa Gullulu.   

Abstract

AIM: To evaluate the association between arterial stiffness and inflammatory markers including C-reactive protein (CRP), pentraxin 3 (PTX3) and neutrophil-to-lymphocyte ratio (NLR) in autosomal dominant polycystic kidney disease (ADPKD) patients with preserved renal function.
METHODS: A total of 52 ADPKD patients [mean (SD) age 38.2 (12.8) years, 69.2 % were females] with preserved renal function and 25 healthy volunteers [mean (SD) age 35.5 (6.5) years, 48.0 % were females] were included. Data on patient characteristics, blood biochemistry, inflammatory markers [PTX3 (pg/mL), CRP (mg/dL) and NLR] and arterial stiffness [large artery elasticity index (LAEI) (mL/mmHg × 10) and small artery elasticity index (SAEI) (mL/mmHg × 100)] were recorded in patient and control groups. Correlation between inflammatory markers and arterial stiffness parameters was analysed in patients.
RESULTS: Overall, 42.3 % of ADPKD patients were hypertensive and 44.4 % were receiving renin-angiotensin-aldosterone system (RAAS) blockade therapy. Median levels for PTX3 [442.0 (20.0-4140.0) pg/mL vs. 220.5 (14.7-393.0) pg/mL, p < 0.001] and SAEI [4.90 (1.60-11.80) mL/mmHg × 100 vs. 6.45 (2.80-15.70) mL/mmHg × 10, p = 0.013] were significantly higher in ADPKD patients than in controls. PTX3 and CRP were not correlated with arterial elasticity, while NLR was significantly correlated with LAEI negatively (Rho = -0.278, p = 0.042).
CONCLUSION: In conclusion, our findings revealed increased PTX3 levels and reduced SAEI in patients as compared with controls, while no correlation between inflammatory markers studied and the small artery elasticity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26047596     DOI: 10.1007/s11255-015-1022-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  44 in total

Review 1.  Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2001-01       Impact factor: 10.121

2.  Arterial dysfunction in early autosomal dominant polycystic kidney disease independent of fibroblast growth factor 23.

Authors:  Abdulmecit Yildiz; Cuma Bulent Gul; Alparslan Ersoy; Burak Asiltas; Selime Ermurat; Selda Dogan; Kemal Karaagac; Saim Sag; Aysegul Oruc; Nimet Aktas; Gokhan Ocakoglu; Ibrahim Dogan; Sumeyye Gullulu; Mustafa Gullulu
Journal:  Iran J Kidney Dis       Date:  2014-11       Impact factor: 0.892

3.  First- and third-order models for determining arterial compliance.

Authors:  S M Finkelstein; J N Cohn
Journal:  J Hypertens Suppl       Date:  1992-08

4.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

5.  Prognostic impact of arterial stiffness in patients with symptomatic peripheral arterial disease.

Authors:  J Kals; J Lieberg; P Kampus; M Zagura; J Eha; M Zilmer
Journal:  Eur J Vasc Endovasc Surg       Date:  2014-06-22       Impact factor: 7.069

6.  Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.

Authors:  R D Perrone; R Ruthazer; N C Terrin
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

7.  Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function.

Authors:  Malene L Borresen; Dan Wang; Svend Strandgaard
Journal:  Am J Nephrol       Date:  2007-03-27       Impact factor: 3.754

8.  The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.

Authors:  M E Suliman; A R Qureshi; J J Carrero; P Bárány; M I Yilmaz; S Snaedal-Jonsdottir; A Alvestrand; O Heimbürger; B Lindholm; P Stenvinkel
Journal:  QJM       Date:  2008-02-20

9.  Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality.

Authors:  Mengli Tong; Juan Jesús Carrero; A Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Jonas Axelsson; Anders Alvestrand; Peter Stenvinkel; Bengt Lindholm; Mohamed E Suliman
Journal:  Clin J Am Soc Nephrol       Date:  2007-08-16       Impact factor: 8.237

10.  Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.

Authors:  Anna Witasp; Mikael Rydén; Juan Jesús Carrero; Abdul Rashid Qureshi; Louise Nordfors; Erik Näslund; Folke Hammarqvist; Samsul Arefin; Karolina Kublickiene; Peter Stenvinkel
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

View more
  2 in total

Review 1.  Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases.

Authors:  Ioana Mozos; Clemens Malainer; Jarosław Horbańczuk; Cristina Gug; Dana Stoian; Constantin Tudor Luca; Atanas G Atanasov
Journal:  Front Immunol       Date:  2017-08-31       Impact factor: 7.561

2.  Association between neutrophil-lymphocyte ratio and arterial stiffness in patients with acute coronary syndrome.

Authors:  Yanyan Li; Xiaofang Chen; Lingzhi Huang; Jinyang Lu
Journal:  Biosci Rep       Date:  2019-05-03       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.